Boxer Capital HCAT Position
Exited3-Fund ConvergenceBoxer Capital exited their position in Health Catalyst, Inc. (HCAT) in Q1 2023, after holding the stock for 5 quarters.
The position was first reported in Q1 2022 and has been tracked across 5 quarterly 13F filings.
HCAT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for MHS-1031 in 45 days (May 31, 2026), making the timing of Boxer's position particularly relevant.
Short interest stands at 11.3% of float with 6.7 days to cover, indicating significant bearish positioning against the stock.
About Health Catalyst, Inc.
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Full company profile →Short Interest
11.3%
6.7 days to cover
Boxer Capital HCAT Position History
Frequently Asked Questions
Does Boxer Capital own HCAT?
No. Boxer Capital exited their position in Health Catalyst, Inc. (HCAT) in Q1 2023. They previously held the stock for 5 quarters.
How many hedge funds own HCAT?
3 specialist biotech hedge funds currently hold HCAT, including Deerfield Management, Rock Springs Capital, RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Boxer Capital first buy HCAT?
Boxer Capital's position in HCAT was first reported in Q1 2022. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Boxer Capital's HCAT position increasing or decreasing?
Boxer Capital completely exited their HCAT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HCATCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Boxer CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →